• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly.

作者信息

Berry C, Norrie J, McMurray J J

出版信息

Am J Cardiol. 2001 Mar 1;87(5):606-7, A9. doi: 10.1016/s0002-9149(00)01439-9.

DOI:10.1016/s0002-9149(00)01439-9
PMID:11230847
Abstract

In the light of the recent randomized controlled trials in chronic heart failure, it is now commonly assumed that treatment with an angiotensin-receptor blocker (ARB) is equivalent to treatment with an angiotensin-converting enzyme (ACE) inhibitor. We performed an imputed placebo analysis using previous placebo-ACE inhibitor trials and the current ACE inhibitor-ARB comparison studies, which shows that ARBs may not even be superior to placebos, let alone an ACE inhibitor.

摘要

相似文献

1
Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly.
Am J Cardiol. 2001 Mar 1;87(5):606-7, A9. doi: 10.1016/s0002-9149(00)01439-9.
2
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.血管紧张素II受体拮抗剂与心力衰竭：血管紧张素转换酶抑制剂仍是一线选择。
Prescrire Int. 2005 Oct;14(79):180-6.
3
[ELITE II. AT1-blockers not better, but more tolerable than ACE-inhibitors].[ELITE II研究：血管紧张素II受体拮抗剂不比血管紧张素转换酶抑制剂好，但耐受性更佳]
Internist (Berl). 2000 Jan;41(1):A37.
4
[A-II blocker or ACE inhibitor in heart failure? Captopril can't be beat].
MMW Fortschr Med. 1999 Nov 25;141(47):4-5.
5
[Interview with the author of ELITE II. Cave: small studies of fatal illnesses].
MMW Fortschr Med. 1999 Nov 25;141(47):6.
6
Evaluation of Losartan in the Elderly (ELITE) Trial: clinical implications.
Eur Heart J. 1997 Aug;18(8):1197-9. doi: 10.1093/oxfordjournals.eurheartj.a015425.
7
Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group.
Lancet. 1999 Jul 31;354(9176):395-6. doi: 10.1016/s0140-6736(99)01354-9.
8
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).氯沙坦与卡托普利治疗65岁以上心力衰竭患者的随机试验（老年氯沙坦评估研究，ELITE）
Lancet. 1997 Mar 15;349(9054):747-52. doi: 10.1016/s0140-6736(97)01187-2.
9
Comparison of losartan and captopril in ELITE II.
Lancet. 2000 Sep 2;356(9232):851; author reply 852-3. doi: 10.1016/S0140-6736(00)02667-2.
10
[Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].[血管紧张素受体阻滞剂治疗充血性心力衰竭患者的随机试验综述]
Nihon Rinsho. 2001 Oct;59(10):2051-61.

引用本文的文献

1
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.β受体阻滞剂和肾素-血管紧张素-醛固酮系统抑制剂用于射血分数保留的慢性心力衰竭。
Cochrane Database Syst Rev. 2021 May 22;5(5):CD012721. doi: 10.1002/14651858.CD012721.pub3.
2
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.用于射血分数保留的慢性心力衰竭的β受体阻滞剂和肾素-血管紧张素-醛固酮系统抑制剂。
Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD012721. doi: 10.1002/14651858.CD012721.pub2.
3
Protection against age-dependent renal injury in the F344xBrown Norway male rat is associated with maintained nitric oxide synthase.
保护 F344xBrown Norway 雄性大鼠免受年龄相关的肾损伤与维持一氧化氮合酶有关。
Mech Ageing Dev. 2011 Jan-Feb;132(1-2):1-7. doi: 10.1016/j.mad.2010.10.004. Epub 2010 Nov 16.